Anti-afucosylated IgG Antibody (SAA2867) from ProteoGenix; catalogue ARO-A22813; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Introducing Anti-afucosylated IgG Antibody (SAA2867), a highly specific and potent tool for researchers in the field of biotechnology. This cutting-edge antibody is designed to target the afucosylated form of IgG, a crucial protein in the immune system.
The afucosylated form of IgG plays a critical role in regulating immune responses, making it an important target for research in various disease states. This form of IgG is known to enhance antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to increased immune response and inflammation. By specifically targeting this form of IgG, our Anti-afucosylated IgG Antibody (SAA2867) provides researchers with a valuable tool to study and understand the immune system.
Our Anti-afucosylated IgG Antibody (SAA2867) has a wide range of applications in the field of biotechnology. It can be used in various immunoassays, including ELISA, Western blot, and immunohistochemistry, to detect and quantify the afucosylated form of IgG. This antibody can also be used in functional studies to investigate the role of afucosylated IgG in immune responses and diseases. Additionally, it can be used in drug discovery and development to evaluate the efficacy of potential therapeutic agents targeting this form of IgG.
The versatility of our Anti-afucosylated IgG Antibody (SAA2867) makes it a valuable tool for a variety of research studies. For example, it can be used to study the role of afucosylated IgG in autoimmune diseases, such as rheumatoid arthritis and lupus. It can also be used to investigate the role of this form of IgG in cancer, as it has been shown to play a role in tumor growth and metastasis. Furthermore, our antibody can be used to evaluate the effectiveness of immune therapies targeting afucosylated IgG in diseases such as HIV and hepatitis.
In conclusion, Anti-afucosylated IgG Antibody (SAA2867) is a highly specific and potent tool for researchers in the field of biotechnology. Its ability to target the afucosylated form of IgG makes it a valuable asset in studying immune responses and diseases. With its wide range of applications and potential use cases, this antibody is a must-have for any laboratory conducting research in the field of immunology. Order now and take your research to the next level.
ProteoGenix catalogue number ARO-A22813. For research use only.
Target: afucosylated IgG, IgG; Clonality: Monoclonal Antibody; Applications: ELISA.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| afucosylated IgG, IgG |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
